Drug intelligence / Profile preview

abbv-927 + nab-paclitaxel + abbv-368

Development stage: Unknown
Lead developer: AbbVie
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

**ABBV-927 + nab-paclitaxel + ABBV-368** is an investigational combination regimen for cancer therapy, specifically explored in early-phase trials for advanced and metastatic solid tumors such as non-small cell lung cancer and triple-negative breast cancer. - **ABBV-927** is a monoclonal antibody agonist targeting CD40, a costimulatory molecule critical for both innate and adaptive immune system activation, essential in T-cell activation and proliferation. - **ABBV-368** is a monoclonal antibody agonist of OX40, another costimulatory molecule that enhances immune response and suppresses regulatory T-cell activity. - **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel) is a chemotherapeutic microtubule inhibitor used routinely to treat various cancers. This triplet aims to provide both immune activation (via CD40 and OX40 agonism) and cytotoxic action (via paclitaxel) to improve antitumor outcomes. The combination is being evaluated by AbbVie in Phase 1 clinical studies for solid tumors[1][5][7].

Brand names: None found specific to this unique triplet combination
Other names: None found specific to this unique triplet combination

Targets

CD28 (Cluster of Differentiation 28)CD40 (Cluster of differentiation 40 receptor)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on abbv-927 + nab-paclitaxel + abbv-368.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abbv-927 + nab-paclitaxel + abbv-368.

Explore the full profile